Mark Bach
Chief Medical Officer GentiBio
Seminars
Wednesday 24th March 2027
Advancing Clinical Development in Type 1 Diabetes Through Treg Therapies That Deliver Durable Immune Tolerance
12:00 pm
- Reviewing emerging clinical insights from Treg therapies in Type 1 Diabetes to assess potential for durable disease modification
- Evaluating clinical endpoints that capture immune tolerance and long-term therapeutic benefit beyond conventional disease measures
- Addressing regulatory and development challenges to support the successful advancement of next-generation Treg therapies in autoimmune disease